Ruthenium anticancer drugs.
Alessio
Enzo
E
Department of Chemical Sciences, University of Trieste, Via L. Giorgieri 1, I-34127 Trieste, Italy. alessi@univ.trieste.it
Mestroni
Giovanni
G
Bergamo
Alberta
A
Sava
Gianni
G
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects; D004121:Dimethyl Sulfoxide / Q000031:analogs & derivatives* / Q000737:chemistry; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D009361:Neoplasm Invasiveness / Q000517:prevention & control; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009369:Neoplasms / Q000473:pathology; D009942:Organometallic Compounds / Q000737:chemistry; D017975:Ruthenium Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; C113661:imidazolium-bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III); D020928:Mitogen-Activated Protein Kinases; D004121:Dimethyl Sulfoxide